Rocket Pharmaceuticals (RCKT) Payables (2014 - 2026)

Rocket Pharmaceuticals has reported Payables for 13 years, with the latest figure at $21.5 million in Q1 2026.

• Quarterly Payables fell 33.58% year-over-year to $21.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.5 million (down 33.58% YoY) and the FY2025 annual result came in at $27.3 million, down 27.85% from the prior year.
• Payables slipped to $21.5 million in Q1 2026 per RCKT's latest filing, from $27.3 million in the prior quarter.
• Over five years, Payables peaked at $45.8 million in Q4 2023 and troughed at $20.0 million in Q1 2022.
• A 5-year average of $31.3 million and a median of $30.6 million in 2023 frame the typical range for Payables.
• The widest YoY moves for Payables: up 86.9% in 2022, down 47.5% in 2022.
• Over 5 years, Payables stood at $36.7 million in 2022, then advanced by 24.9% to $45.8 million in 2023, then slipped by 17.39% to $37.8 million in 2024, then fell by 27.85% to $27.3 million in 2025, then retreated by 21.07% to $21.5 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $21.5 million, $27.3 million, and $28.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.